BACKGROUND Slow delayed-rectifier potassium current (I Ks ) channels, made of the pore-forming KCNQ1 and auxiliary KCNE1 subunits, play a key role in determining action potential duration (APD) in cardiac myocytes. The consequences of drug-induced KCNQ1 splice alteration remain unknown.
Introduction
Ventricular repolarization is significantly dependent on slow delayed-rectifier potassium current (I Ks ), and the contribution of I Ks to action potential (AP) repolarization is enhanced during beta-adrenergic stimulation. [1] [2] [3] [4] This enhancement is also reflected in the phenotype of most long QT syndrome type 1, which is caused by KCNQ1 (α-subunit of I Ks ) mutations, with ventricular arrhythmias mostly occurring under physical or emotional stress. Phosphorylation by protein kinase A (PKA) following beta-adrenergic receptor stimulation greatly enhances I Ks by increasing current amplitude, by leftward shift in the current-voltage curve, and by changing activation and deactivation kinetics. 2, 4 In large mammals, I Ks also constitutes a "repolarization reserve" that compensates for compromised other repolarization currents, in particular rapid delayed-rectifier potassium current. 3, 4 A weaker I Ks contributes partially to the longer AP in midmyocardial (Mid) myocytes, and a prominent I Ks enables endocardial (Endo) and epicardial (Epi) myocytes to be more resistant to early afterdepolarization (EAD) activity than Mid myocytes. 5, 6 In the human and the canine heart, there are 2 splicing variants of KCNQ1. One is full-length, KCNQ1a, and the other is N-terminal truncated, KCNQ1b. 7, 8 KCNQ1b exerts a dominant negative effect owing to a trafficking defect, and KCNQ1b transgenic mice manifest with pronounced QT prolongation and ventricular arrhythmias. [7] [8] [9] The differential expression of KCNQ1 splicing variants has been suggested to be responsible for differential I Ks amplitude and also for AP heterogeneity across the ventricular wall. 9 However, whether splicing of KCNQ1 can be altered and how such alterations affect cardiac arrhythmogenicity remain unexplored.
Amiloride, a potassium-sparing diuretic for the treatment of hypertension and congestive heart failure since 1967, has multiple pharmacological actions. Our previous studies showed that splicing site selection in several genes can be altered by amiloride. 10, 11 Prolonged treatment with amiloride also exerts an antiarrhythmic effect both in postinfarction dogs and in patients with ventricular tachycardia. 12, 13 However, cellular mechanisms have not been determined.
Here, we study the electrophysiological effects of amiloride on ventricular myocytes, in terms of its effect on KCNQ1 splicing variants expression and I Ks densities, as well as investigate the effect of KCNQ1 splicing on the action potential duration (APD), isoproterenol (ISO)-induced EAD, and cardiac transmural dispersion of repolarization (TDR). The mechanism of how amiloride affects arrhythmogenicity is also addressed.
Methods
An expanded, detailed methods section is provided in the Online Supplemental Material.
Electrophysiology
The Xenopus oocytes expressed with human KCNQ1 and KCNE1 were used to examine the acute effect of amiloride and the dominant negative effect of KCNQ1b on currents (see Figure 2) . Myocyte whole-cell patch clamp was performed at 36.51C with Tyrode's solution (see Figures 3  and 4) . We recorded AP after 6 hours of incubation time with or without 50 μmol/L of amiloride. Myocytes with APDs after stabilization outside the 250-450 ms range were not included for analysis.
Biochemistry
To study the effect of amiloride on KCNQ1 splicing, freshly isolated canine myocytes were incubated in either M199 culture medium (Sigma, St Louis, MO) or M199 with 50 μmol/L of amiloride (Sigma) at 371C in a humidified 5% CO 2 incubator. The amiloride concentration of 50 μmol/L was according to the plasma level in clinical use.
14 After 6 hours, cells were resuspended, washed, and homogenized in Trizol (Invitrogen, Grand Island, NY) for RNA extraction or in protein lysis buffer for protein extraction. The reverse transcriptase-polymerase chain reaction (RT-PCR) of the controlled RNA amount (50 ng) was performed by using primers for total KCNQ1, KCNQ1a, and KCNE1. The quantification of mRNA expression levels of total KCNQ1 and KCNQ1a were studied by performing real-time PCR using a LightCycler instrument (Roche, Indianapolis, IN) with the universal probe system. Western blotting was performed by using specific antibodies shown in Figure 1 . Differences were considered statistically significant if P o .05 (by the Student t test).
Model simulations
The simulations of cardiac APs are based on a modified O'Hara-Rudy (ORd) model of human ventricular cardiomyocytes, in which the signaling cascade from ISO application to PKA phosphorylation of target proteins was incorporated. [15] [16] [17] The parameters affected by PKA phosphorylation were computed by using the Heijman et al model of the beta-adrenergic signaling pathway. 16 The I Ks densities used in the simulations during baseline and under ISO for different KCNQ1b/total KCNQ1 ratios were from published data and our experimental results. 9 To determine how the KCNQ1b/total KCNQ1 ratio affects repolarization in the context of heterogeneous heart tissue, simulations on a 1-dimensional transmural wedge were performed. 18 
Results

KCNQ1 splicing variants expression was changed by amiloride treatment in canine cardiomyocytes
The effect of amiloride on KCNQ1 splicing was tested in freshly isolated canine cardiomyocytes. The analysis of RT-PCR products ( Figure 1A ) indicated that the expression of KCNQ1a was differentially changed by amiloride in Endo, Mid, and Epi myocytes ( Figures 1B-1H ). Compared to the corresponding control myocytes the transcript of KCNQ1a was higher in the amiloride-treated group in Mid myocytes (1.39 Ϯ 0.08 fold to control) but lower in Endo (0.84 Ϯ 0.06 fold to control) and Epi (0.82 Ϯ 0.02 fold to control) myocytes. The transcriptional expression of total KCNQ1 did not differ in Endo, Mid, or Epi myocytes between the amiloride-treated and the corresponding control group (0.99 Ϯ 0.05, 0.98 Ϯ 0.04, and 0.93 Ϯ 0.05 folds to control, respectively). The transcriptional expression of total KCNQ1 and KCNQ1a were also quantified by the real-time PCR ( Figure 1L ). The expression of total KCNQ1 did not differ in Endo, Mid, or Epi myocytes between the amiloride-treated and corresponding control groups (1.03 Ϯ 0.04, 1.08 Ϯ 0.16, and 1.03 Ϯ 0.07 folds to control, respectively). The transcript of KCNQ1a was higher in the amiloride-treated group in Mid myocytes (1.43 Ϯ 0.25 fold to control) but lower in Endo myocytes (0.75 Ϯ 0.08 fold to control). Protein expression changes were consistent with transcriptional changes in KCNQ1. The KCNQ1 protein migrates in sodium dodecyl sulfate polyacrylamide gel electrophoresis with a molecular mass of 75 kDa for KCNQ1a and 60 kDa for KCNQ1b ( Figure 1G ). 
Multiple splicing factors may cause opposite changes in Mid myocytes compared to Endo and Epi myocytes
Splicing regulation involves a large number of RNA-binding proteins, with SR proteins and hnRNPs being the 2 largest families that function by a wide variety of mechanisms. 19 We used Western blot to determine the effect of amiloride on the expression of several splicing-associated proteins to examine whether the differential regulation of KCNQ1 splicing variants in various types of myocytes by amiloride is a result of the changes in splicing factors. The splicing factors tested include hnRNP-R, hnRNP-I, hnRNP-C1/C2, hnRNP-A1, SF2, and SRP20 ( Figures 1I-1K) , and the amilorideinduced changes in some splicing factors in Mid myocytes were opposite to those in Endo and Epi myocytes. For instance, with amiloride treatment, hnRNP-R expression significantly increased in Endo and Epi myocytes but decreased in Mid myocytes while hnRNP-C1/C2 and SRP20 expression significantly decreased in Endo and Epi myocytes but increased in Mid myocytes.
Acute effect of amiloride on KCNQ1 and I Ks channels
The amiloride-induced changes in KCNQ1 expression may affect the electrophysiological properties of the heart (see below). To examine whether amiloride can also alter heart function by acutely altering I Ks channel function, we treated amiloride on human KCNQ1 and KCNQ1þKCNE1 (I Ks ) channels expressed in Xenopus oocytes. Amiloride did not change the peak amplitudes of KCNQ1 (n ¼ 4) current or I Ks (n ¼ 7) (Figures 2A and 2B) . The conductance-voltage (G-V) relationships of KCNQ1 current and I Ks showed that amiloride did not change voltage-dependent activation of the channels (V 1/2 for KCNQ1: amiloride-treated group −22.3 Ϯ 5.2 mV; control group −19.7 Ϯ 6.9 mV, P 4 .05; for I Ks : amiloride-treated group 29.7 Ϯ 5.8 mV; control group 30.4 Ϯ 4.9 mV, P 4 .05). There is a slope change in the G-V relationship of KCNQ1 after amiloride treatment (amiloridetreated group 14.7 Ϯ 2.4; control group 9.5 Ϯ 1.5, P ¼ .01).
However, the slope for I Ks did not change with amiloride (amiloride-treated group 14.6 Ϯ 2.5; control group 13.2 Ϯ 2.6, P 4 .05) ( Figure 2C ). Amiloride also did not change the activation time ( Figure 2D ). These experiments demonstrated that amiloride does not directly affect the I Ks channel function.
KCNQ1b exerts dominant negative effect on KCNQ1 current and I Ks
To assess the dominant negative effect of KCNQ1b quantitatively, we measured the dependence of KCNQ1 and I Ks current amplitude on the KCNQ1b/total KCNQ1 mRNA ratio with a fixed amount of KCNQ1a and KCNE1 mRNA co-injection in Xenopus oocytes ( Figures 2E and 2F) . The KCNQ1 and I Ks current amplitudes decreased with increasing KCNQ1b/total KCNQ1 mRNA ratio. KCNQ1 and I Ks channels contain 4 KCNQ1 subunits. It is possible that a channel containing any (1-4) KCNQ1b subunit is not functional. To test this possibility, we assumed that the population of KCNQ1 and I Ks channels containing 0-4 KCNQ1b subunits follows a binomial distribution on the basis of the KCNQ1b/total KCNQ1 mRNA ratio and only the channels containing no KCNQ1b are functional. This model prediction of the dominant negative effect of KCNQ1b fits well with the experimental results ( Figure 2F ).
Introduction of the dominant negative effect of KCNQ1b on I Ks into the simulations of human ventricular myocyte AP
The amiloride-induced changes in KCNQ1 splicing variants may affect the APs of cardiac myocytes. To examine whether amiloride can alter the human cardiac AP, we first performed a simulation by using the ORd model. 15 To define specific I Ks conductance in different types of myocytes for AP simulations, we adopted a previous study result showing differential KCNQ1b expression across the human ventricle (see the Online Supplemental Table) . 9 In their quantitative RT-PCR, KCNQ1b represented 25.2% Ϯ 2.3%, 31.7% Ϯ 1.2%, and 24.9% Ϯ 1.7% of total KCNQ1 expression in left ventricular Endo, Mid, and Epi tissues, respectively. We used the model prediction of the dominant negative effect of KCNQ1b ( Figure 2F ) to determine human I Ks conductance on the basis of the KCNQ1b/total KCNQ1 ratio ( Figure 3A) . Because there is no significant differential expression of total KCNQ1 mRNA ( Figure 1C) , 9 the KCNQ1b/total KCNQ1 ratios of 0.252 for Endo, 0.317 for Mid, and 0.249 for Epi myocytes were used. The normalized I Ks conductance of control human myocytes was thus 0.31 for Endo, 0.22 for Mid, and 0.32 for Epi myocytes, respectively ( Figure 3A) . We then used our biochemistry results (Figure 1) Figure 1C ), KCNQ1b/total KCNQ1 ratios for amiloride-treated myocytes was 0.380, 0.104, and 0.378 for Endo, Mid, and Epi myocytes, respectively. Thus, the normalized I Ks conductance of human Endo, Mid, and Epi myocytes after amiloride treatment was 0.15, 0.64, and 0.15 ( Figure 3A) , with a 0.47, 2.96, and 0.47 fold change compared to control myocytes, respectively. These factors were used for subsequent AP simulations. For Mid myocytes, AP simulations at a cycle length (CL) of 1000 ms showed that APDs were shorter in amiloride treatment ( Figure 3B ) and the shortening was the same in the absence and presence of ISO (shortening was 34. Figure 2 Acute effect of amiloride and effect of KCNQ1b on KCNQ1 current and slow delayed-rectifier potassium current (I Ks ). A: Human KCNQ1 and I Ks (KCNQ1aþKCNE1) currents expressed in Xenopus oocytes before and after acute amiloride treatment. Currents were elicited by voltage pulses from -80 to þ60 mV with 10 mV increment; the holding and repolarization potentials were -80 and -40 mV, respectively. B: KCNQ1a and I Ks peak tail currents following depolarization to þ40 mV at various times (n ¼ 3 for KCNQ1a and n ¼ 6 for I Ks ). Open symbol is for currents without amiloride application during the entire recordings (control group); filled symbol is for currents recorded before and during amiloride application, with the gray box indicating the period of administration (amiloride group). C: Conductance-voltage (G-V) relationships of normalized KCNQ1a and I Ks tail currents with and without amiloride treatment (n ¼ 5 for each). D: Voltage dependence of activation times of KCNQ1a current and I Ks . τ As and τ Af are obtained from fitting the activating current traces with a double exponential function. E: I Ks from oocytes with an injection of 4 ng of KCNQ1a, 3.5 ng of KCNE1, and 0-8 ng of KCNQ1b mRNA. F: I Ks and KCNQ1 current amplitudes depend on the KCNQ1b/total KCNQ1 mRNA ratio. Peak currents were normalized to that without KCNQ1b co-injection. The curve of predicted dominant negative effect (see text) is shown by the dotted line.
amiloride-treated Mid myocytes under baseline conditions (P ¼ .01), and the shortening was from 289 Ϯ 39 ms in control myocytes to 249 Ϯ 31 ms in amiloride-treated Mid myocytes in the presence of ISO (P ¼ .16) (Figures 3C and 3D) .
In addition, the difference in APD between control and amiloride-treated Mid myocytes increased while the pacing CL shortened (faster rate) in both experiments and model simulations. Experimentally, APD in amiloride-treated myocytes was 11.7%, 10.4%, and 7.5% shorter than in control myocytes at CLs of 500, 1000, and 2000 ms, respectively. In human Mid myocyte AP simulations, the APD was shortened by increasing I Ks conductance 2.96 times ( Figure 3A) , and APD shortening was also enhanced at fast rates (9.7%, 9.2%, and 8.8% shorter than in control myocytes at CLs of 500, 1000, and 2000 ms, respectively) ( Figure 3E ). This phenomenon is due to an important I Ks role in the rate adaptation of APD, by which I Ks facilitates AP repolarization acceleration and APD shortening at fast rates. 3 The frequency dependence of amiloride induced APD shortening in both experiments, and simulation further supports that APD shortening was derived from enhanced I Ks current by amiloride treatment. 
Amiloride treatment reduced the occurrence of EADs under ISO challenge in Mid myocytes
For canine left ventricular myocytes, ISO at concentrations as low as 20 nmol/L can induce EADs. 20 To examine whether amiloride can affect the development of ISOinduced EADs at both slow and fast rates, we performed AP recordings in canine Mid myocytes with ISO challenge by using gradual titration. The threshold of ISO concentration for inducing EADs in our canine Mid myocytes was 20 or 50 nmol/L and was not different between control and amiloride-treated myocytes. However, EADs were generated more frequently in control than in amiloride-treated myocytes ( Figures 4A-4C) . In both control and amiloride-treated Mid myocytes, EADs were more frequently generated at slower rates ( Figure 4C ).
To evaluate the effect of amiloride on EAD generation, we used the ORd model, in which a series of modifications in the equations were incorporated to account for beta-adrenergic stimulation (see the Online Supplemental Material). Previous studies have shown that under steady-state pacing at CL of 1000 ms, the application of 1 μmol/L of ISO led to EAD generation even in normal Mid myocyte AP simulations, partially because ISO-induced phosphorylation is faster in Ltype calcium current (I CaL ) than in I Ks . 17, 21 Our simulations revealed that at slower pacing EADs appeared in both control and amiloride-treated Mid myocytes after ISO application ( Figure 4D ). Less EADs were generated at fast pacing rate and they were inhibited by amiloride. The EADs were associated with I CaL reactivation, while the increased I Ks conductance caused shortening of APD and reduced I CaL reactivation. EAD was not noted in either Endo or Epi AP simulations under ISO challenge (data not shown). The simulations suggest that amiloride-induced 2.96-fold I Ks conductance increase can inhibit EAD generation in human ventricular Mid myocytes under the challenge of high concentrations of ISO.
Discussion
The results of the present study suggest that (1) amiloride changes the alternative splicing of KCNQ1 and that effect may be caused by splicing factor changes, (2) a prominent I Ks density modulation can be attributed to a small change in KCNQ1b splicing variant expression, and (3) in Mid myocytes, increased I Ks density shortens APD and inhibits EADs development under beta-adrenergic stimulation. Amiloride has multiple pharmacological actions on ionic channels and transporters. It inhibits the Na/H exchanger in cultured cardiac cells and in sheep Purkinje fibers; nonetheless, Na/H exchange inhibition by 0.01-1.0 mmol/L of amiloride does not cause intracellular acidosis. 22 Amiloride also suppresses the T-type calcium current in guinea pig ventricular myocytes with a dissociation constant Kd of 233 μmol/L and inhibits sarcolemmal Na þ / Ca 2þ exchanger with half maximal effective concentration EC 50 at 0.7 mmol/L in isolated beating guinea pig atria. 23, 24 The amiloride concentration of 50 μmol/L used in this study is too low to affect the intracellular pH or to inhibit the T-type calcium current and the Na þ /Ca 2þ exchanger. Amiloride (10 μmol/L) was shown to prolong APD with prolonged treatment in canine cardiac Purkinje fibers. 25 Whether amiloride could change KCNQ1 splicing (with increased KCNQ1b expression) in Purkinje fibers remains to be determined.
Other genetic factors have been shown to modify KCNQ1 transcript expression and QT interval, for example, variants in the 3′ untranslated region of KCNQ1, variants in putative ion channel regulatory subunits such as NOS1AP, and stimulating protein 1 which is involved in transcriptional activation of the KCNQ1 promoter. [26] [27] [28] To our knowledge, this is the first report describing drug-induced alternative splicing of KCNQ1 in cardiac myocytes. The detailed mechanism involved in KCNQ1 splicing remains to be investigated.
Clinical implications
QT dispersion, which is the difference in minimal QT interval and maximal QT interval in the surface 12-lead electrocardiogram (ECG), has been suggested to reflect repolarization inhomogeneity in the heart and to have association with sudden cardiac death in healthy subjects and in patients with chronic heart failure. 29, 30 In a double-blinded clinical study, amiloride significantly reduced QT dispersion and also reduced ventricular extrasystoles. 31 Simulated pseudo-ECG establishes a direct relationship between ionic currents, the AP, and the morphology of electrocardiographic waveforms. It allows us to evaluate the effect of amiloride on the ECG QT interval without performing an in vivo study ( Figure 5 ). We introduced the estimated I Ks conductance of Endo, Mid, and Epi in the amiloride simulations as 0.47, 2.96, and 0.47 times control ( Figures 3A and 5) . Moreover, owing to the nature of potassium sparing diuretics, amiloride increases plasma potassium by an average value of 0.5 mmol/L. 12, 13, 31 Therefore, we further simulated APs and pseudo-ECGs with increased extracellular K þ level by 0.5 mmol/L ( Figure 5 ). In AP simulations, the reduced I Ks conductance caused APD prolongation with 8 ms for Endo and 4.7 ms for Epi myocytes ( Figure 5) ; however, these prolongations were offset by the elevation of K þ level (APD changes were only 0.8 ms for Endo and −0.9 ms for Epi). The above clinical study also observed that the potassium elevation shortened QT interval. 31 The heterogeneity of the I Ks conductance among 3 transmural layers was enlarged by amiloride ( Figure 3A) ; nonetheless, APD differences and TDR were reduced because of major increase of Mid I Ks and shortening of its APD ( Figure 5 ). The reduction of TDR by amiloride was frequency dependent and was larger at a faster pacing rate (14%, 16.7%, and 25.8% reduction with amiloride compared to the control at CLs of 2000, 1000, and 500 ms, respectively) ( Figure S1 ). These results suggest that reduced dispersion may be an antiarrhythmic mechanism of amiloride in the clinical setting. 30 This study also suggests that the alternative splicing of KCNQ1 may be an antiarrhythmic therapeutic target.
In conclusion, amiloride induces KCNQ1 splicing changes by affecting the expression of splicing factors and the effects show transmural differences. This drug-induced modulation of I Ks due to the alternative splicing of KCNQ1 changes the I Ks transmural heterogeneity and results in reduced transmural dispersion, reduced EAD formation and therefore reduced arrhythmogenicity under beta-adrenergic stimulation.
